There is currently no evidence available that inhaled insulin (Exubera) in diabetes therapy shows advantages over short-acting human insulin or insulin analogues administered subcutaneously. The ...

Feb. 9, 2006 -- Despite initial concerns regarding lung function, the US Food and Drug Administration (FDA) approved Pfizer's inhaled insulin Exubera for adult patients with type 1 and type 2 diabetes ...

Pfizer will mount a branded DTC advertising campaign behind Exubera as it attempts to turn around the “disappointing” sales of the inhaled insulin product. “While we remain convinced that Exubera ...

A headline incorrectly stated that Pfizer will buy rights for Exubera inhaled insulin from San Carlos biotech company Nektar Therapeutics. Pfizer actually paid to end its marketing of Exubera. The ...

Pfizer said it would delay the launch of its inhaled insulin Exubera until early September, weeks later than its previously anticipated delivery date of mid-July. Pfizer executives said Thursday in a ...

Pfizer Inc., the world’s largest pharmaceutical company, said its third-quarter profit plunged due to a $2.8 billion pretax charge to end investment in inhaled insulin drug Exubera, and lower sales of ...

Fed up with lackluster sales of Exubera, the groundbreaking inhaled insulin treatment developed by Nektar Therapeutics of San Carlos, New York drug-giant Pfizer said Thursday it will stop selling the ...

Pharmaceutical giant Pfizer recently announced it will stop selling Exubera, a relatively new inhaled insulin product. The tab for this marketing mistake is $2.8 billion, one of the biggest ...

As companies bail out of the inhaled insulin business -- most recently Pfizer, which lost $2.8 billion before throwing Exubera overboard-- one small firm believes there is an alternative to pills, ...

The most disastrous, if least surprising, news from Pfizer's (NYSE:PFE) third-quarter earnings announcement yesterday was its surrender of the rights to market inhalable-insulin treatment Exubera to ...